The text starts here.

News Release

November 5, 2002

Eisai Submits Vascular Dementia Marketing Authorization
Application for ARICEPT (R) in the U.K.

Tokyo (November 5, 2002) Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) has submitted a Variation to the Marketing Authorisation Application (MAA) on October 31, 2002 for ARICEPT (R) (donepezil hydrochloride tablets) for the symptomatic treatment of vascular dementia (VaD) to the Medicines Control Agency which acted as the reference member state for the mutual recognition procedure in Europe.

VaD is second only to Alzheimer's disease as the most common form of dementia in most parts of the world. VaD cognitive decline, most commonly caused by a single localized stroke or series of strokes, accounts for up to 20 percent of patients suffering dementia.

ARICEPT (R) is an acetylcholineterase inhibitor and was synthesized by Eisai Co., Ltd. ARICEPT (R) increases a neurotransmitter in the brain, acetylcholine, and is approved as a symptomatic treatment for mild to moderately severe dementia of the Alzheimer's type. Currently, the product has been launched in over 60 countries worldwide, including Japan, the United States, the United Kingdom, Germany, and France. In the United States a submission for the vascular dementia indication was made to the FDA on September 3, 2002.

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The Company reported sales of over $3.2 billion in 2001 with approximately 13 percent of sales spent for research and development.